Clinical Treatment Efficacy of Percutaneous Coronary Intervention Therapy on Acute Myocardial Infarction Complicated with Multiple Organ Dysfunction Syndrome
American Journal of Life Sciences
Volume 7, Issue 6, December 2019, Pages: 115-119
Received: Sep. 23, 2019; Published: Nov. 8, 2019
Views 17      Downloads 6
Authors
Nana Peng, Department of Emergency, Binzhou People's Hospital, Binzhou City, P. R. China
Binbin Wang, Department of Emergency, Binzhou People's Hospital, Binzhou City, P. R. China
Yucheng Ma, Binzhou Center for Disease Control and Prevention, Binzhou City, P. R. China
Article Tools
Follow on us
Abstract
Objective: This study aims to evaluate the clinical efficacy of the percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI) complicated by multiple organ dysfunction syndrome (MODS). Methods: 216 patients with AMI complicated by MODS hospitalized in the Department of Cardiology of our hospital from January 2011 to March 2013 were divided into a PCI group (n=98) and a drug treatment group (n=118). The basic clinical data, the incidence rate of each dysfunction organ, the number of dysfunction organs and the mortality were compared between the two groups. Results: The rate of patients with ST-segment elevation AMI in the PCI group was higher than in the drug treatment group, and the rate of patients with non-ST-segment elevation AMI was lower than in the drug treatment group (P<0.05). The use of temporary pacemakers and IABP was similar between the two groups (P>0.05). The recanalization rate in PCI group was much higher than that in the drug treatment group (P<0.05). The two groups had similar rates in the incidence of organ dysfunction in the heart, lungs, kidneys, stomach and intestine, etc. and the PCI group had lower organ dysfunction incidence rate in the liver, brain and hematological system than the drug treatment group (P<0.05). The dysfunction incidence rate of 2 organs was higher in PCI group than in drug treatment group (P<0.05), the dysfunction incidence rate of 3 organs was similar between the two groups, and the dysfunction incidence rate of 3 organs or more was significantly lower in PCI group than in drug treatment group (P<0.05). Conclusion: Despite the high risk and high mortality in the patients with AMI complicated by MODS, satisfactory clinical efficacy can still be achieved as long as positive and effective PCI therapy is applied.
Keywords
Myocardial Infarction, Multiple Organ Failure, Percutaneous Coronary Intervention, Treatment Efficacy
To cite this article
Nana Peng, Binbin Wang, Yucheng Ma, Clinical Treatment Efficacy of Percutaneous Coronary Intervention Therapy on Acute Myocardial Infarction Complicated with Multiple Organ Dysfunction Syndrome, American Journal of Life Sciences. Vol. 7, No. 6, 2019, pp. 115-119. doi: 10.11648/j.ajls.20190706.13
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Zhu XY. Qin YW. et al. Long-term efficacy of transcatheter closure of ventricular septal defect in combination with percutaneous coronary intervention in patients with ventricular septal defect complicating acute myocardial infarction: a multicentre study [J]. EuroIntervention, 2018, 8 (11): 1270-6.
[2]
Goel K. Pinto DS. et al. Association of time to reperfusion with left ventricular function and heart failure in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: A systematic review [J]. Am Heart J, 2017, 165 (4): 451-67.
[3]
Bernat I. Abdelaal E. et al. Early and late outcomes after primary percutaneous coronary intervention by radial or femoral approach in patients presenting in acute ST-elevation myocardial infarction and cardiogenic shock [J]. Am Heart J, 2018, 165 (3): 338-43.
[4]
Falsoleiman H. Fatehi GH. et al. Clinical outcome, and survival between primary percutaneous coronary intervention versus fibrinolysis in patients older than 60 years with acute myocardial infarction [J]. Heart Views, 2018, 13 (4): 129-31.
[5]
Sciagra R. Cipollini F. et al. Detection of infarct size safety threshold for left ventricular ejection fraction impairment in acute myocardial infarction successfully treated with primary percutaneous coronary intervention [J]. Eur J Nucl Med Mol Imaging, 2018, 40 (4): 542-7.
[6]
Tok D. Turak O. et al. Primary percutaneous coronary intervention for acute myocardial infarction in elderly aged 75 years and over: in-hospital mortality and clinical outcome [J]. Turk Kardiyol Dern Ars, 2019, 40 (7): 565-73.
[7]
Heitzler VN. Babic Z. et al. Evaluation of importance of door-to-balloon time and total ischemic time in acute myocardial infarction with ST-elevation treated with primary percutaneous coronary intervention [J]. Acta Clin Croat , 2016, 51 (3): 387-95.
[8]
Mylotte D. Morice MC. et al. Primary percutaneous coronary intervention in patients with acute myocardial infarction, resuscitated cardiac arrest, and cardiogenic shock: the role of primary multivessel revascularization [J]. JACC Cardiovasc Interv, 2018, 6 (2): 115-25.
[9]
Tsai TH. Yeh KH. et al. Estimated glomerular filtration rate as a useful predictor of mortality in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention [J]. Am J Med Sci, 2017, 345 (2): 104-11.
[10]
Shacham Y. Leshem-Rubinow E. et al. Frequency and correlates of early left ventricular thrombus formation following anterior wall acute myocardial infarction treated with primary percutaneous coronary intervention [J]. Am J Cardiol, 2018, 111 (5): 667-70.
[11]
Morimoto K. Ito S. et al. Acute effect of sodium nitroprusside on microvascular dysfunction in patients who underwent percutaneous coronary intervention for acute ST-segment elevation myocardial infarction [J]. Int Heart J, 2019, 53 (6): 337-40.
[12]
Patel MR. Westerhout CM. et al. Aborted myocardial infarction after primary percutaneous coronary intervention: magnetic resonance imaging insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial [J]. Am Heart J, 2018, 165 (2): 226-33.
[13]
Oduncu V. Erkol A. et al. The prognostic value of serum albumin levels on admission in patients with acute ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention [J]. Coron Artery Dis, 2017, 24 (2): 88-94.
[14]
Cubeddu RJ. Palacios IF. et al. Outcome of Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention During On-Versus Off-hours (A Harmonizing Outcomes With RevasculariZatiON and Stents in Acute Myocardial Infarction [HORIZONS-AMI] Trial Substudy) [J]. Am J Cardiol, 2017, 111 (7): 946-54.
[15]
Yu J. Mehran R. et al. Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial [J]. JACC Cardiovasc Interv, 2017, 5 (12): 1231-8.
[16]
Lin GM. Li YH. et al. Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial [J]. Am Heart J, 2017, 164 (6): 19-21.
[17]
Cubeddu RJ. Palacios IF. et al. Outcome of Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention During On- Versus Off-hours (A Harmonizing Outcomes With RevasculariZatiON and Stents in Acute Myocardial Infarction [HORIZONS-AMI] Trial Substudy) [J]. Am J Cardiol, 2018, 111 (7): 946-54.
[18]
Nakatani D. Sakata Y. et al. Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in the percutaneous coronary intervention era [J]. Am J Cardiol, 2018, 111 (4): 457-64.
[19]
Harrison RW. Aggarwal A. et al. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction [J]. Am J Cardiol, 2017, 111 (2): 178-84.
[20]
Tsai TH. Sung PH. et al. Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention [J]. J Atheroscler Thromb, 2018, 19 (12): 1073-82.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186